novoGI president and chief executive officer Gavriel Meron said the company is looking forward to the product’s development and success in clinical trials as a potential replacement for the current method of stapled low anterior resections.

"This product is expected to complement the ColonRing, our clinically proven patented nitinol-based compression anastomosis solution which has been evidenced for ease of use, better healing processes, and successful outcomes in regard to leak rates," Meron added.

"The combination of an innovative stapleless low anterior anastomosis solution and our current product can enable us to expand our offering of a completely stapleless resection and anastomosis procedure for colorectal surgeons worldwide.

" We see this agreement as yet another step towards expanding our procedure offerings in line with our focus on advancing patient care and seeking better outcomes through novoGI’s comprehensive approach to GI disease management."